

HLAVNÍ TÉMA

RASTÚCÍ VÝZNAM GENETIKY A KONCEPT GENETICKÉHO TESTOVANIA V OBLASTI ALZHEIMEROVEJ CHOROBY A PRÍBUZNÝCH DEMENCIÍ. SKÚSENOSTI Z JEDNÉHO CENTRA

706. doi:10.1038/349704a0.

11. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors [published correction appears in *Genet Med*. 2011 Aug;13(8):749]. *Genet Med*. 2011;13(6):597-605.

12. Guerreiro R, Brás J, Hardy J. Snapshot: genetics of Alzheimer's disease. *Cell*. 2013;155(4):968-968.e1. doi:10.1016/j.cell.2013.10.037.

13. Herz J, Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. *Nat Rev Neurosci*. 2000;1(1):51-8.

14. Holstege H, Hulsman M, Charbonnier C, et al. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. *Nat Genet*. 2022;54(12):1786-1794. doi:10.1038/s41588-022-01208-7.

15. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet*. 2011;43(5):429-435. doi:10.1038/ng.803.

16. Huang YA, Zhou B, Wernig M, et al. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A β Secretion. *Cell*. 2017;168(3):427-441.e21. doi:10.1016/j.cell.2016.12.044.

17. Javor J, Durmanová V, Párnická Z, et al. Association of CD33 rs3865444:C>A polymorphism with a reduced risk of late-onset Alzheimer's disease in Slovaks is limited to subjects carrying the APOE ϵ 4 allele. *Int J Immunogenet*. 2020;47(5):397-405. doi:10.1111/iji.12489.

18. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol Psychiatry*. 2015;77(1):43-51. doi:10.1016/j.biopsych.2014.05.006.

19. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*. 2013;45(12):1452-1458. doi:10.1038/ng.2802.

20. Liu CC, Kanekiyo T, Xu H, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol*. 2013;9(2):106-118. doi:10.1038/nrneuro.2012.263.

21. Mansoori N, Tripathi M, Luthra K, et al. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogenesis of Alzheimer's and vascular dementia and their epistatic interaction. *Neurobiol Aging*. 2012;33(5):1003.e1-8.

22. Naj AC, Schellenberg GD; Alzheimer's Disease Genetics Consortium (ADGC). Genomic variants, genes, and pathways of Alzheimer's disease: An overview. *Am J Med Genet B Neuropsychiatr Genet*. 2017;174(1):5-26. doi:10.1002/ajmg.b.32499.

23. Noveir SD, Kerman BE, Xian H, et al. Effect of the ABCA1 agonist CS-6253 on amyloid- β and lipoprotein metabolism in cynomolgus monkeys. *Alzheimers Res Ther*. 2022;14(1):87. doi:10.1186/s13195-022-01028-1.

24. Reiman EM. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. *Nature Communications*. 2020;11:667. <https://doi.org/10.1038/s41467-019-14279-8>.

25. Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ 4, and the risk of late-onset Alzheimer disease in African Americans. *JAMA*. 2013;309(14):1483-1492. doi:10.1001/jama.2013.2973.

26. Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer's disease. *Acta Neuropathol*. 2012;124(3):305-323. doi:10.1007/s00401-012-0996-2.

27. Silveira S, König T, Wurm R, et al. Comprehensive genetic screening of early-onset dementia patients in an Austrian cohort suggesting new disease-contributing genes. *Hum Genomics*. 2023;17(1):55. Published 2023 Jun 17. doi:10.1186/s40246-023-00499-z.

28. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci U S A*. 1993;90(5):1977-81.

29. Sutovsky S, Petrovic R, Fischerova M, et al. Allelic Distribution of Genes for Apolipoprotein E and MTHFR in Patients with Alzheimer's Disease and Their Epistatic Interaction. *J Alzheimers Dis*. 2020;77(3):1095-1105. doi:10.3233/JAD-200321.

30. Sutovsky S, Smolek T, Turcani P, et al. Neuropathology and biochemistry of early onset familial Alzheimer's disease caused by presenilin-1 missense mutation Thr116Asn. *J Neural Transm (Vienna)*. 2018;125(6):965-976. doi:10.1007/s00702-018-1850-z.

31. Winfree RL, Seto M, Dumitrescu L, et al. TREM2 gene expression associations with Alzheimer's disease neuropathology are region-specific: implications for cortical versus subcortical microglia. *Acta Neuropathol*. 2023;145(6):733-747. doi:10.1007/s00401-023-02564-2.

32. Zhang MY, Miao L, Li YS, Hu GY. Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to Alzheimer's disease. *Neurosci Res*. 2010;68(2):142-50.

ON-LINE KURZ

On-line kurz pro praktické neurology 2023

PŘEDNÁŠKY

- **Bezpečnost vysoce účinných DMD v léčbě RS** – doc. MUDr. Zbyšek Pavelek, Ph.D.
- **Postavení selektivní imunorekonstituce v léčbě relabující RS**
prof. MUDr. Jan Mareš, Ph.D.
- **Glymfatický systém CNS aneb lekce z neurobiologie na AAN 2022**
MUDr. Jana Lízrová Preiningarová, Ph.D.
- **Poruchy chůze ve stáří** – MUDr. Hana Brožová, Ph.D.
- **Změny kognice ve stáří: jak poznat, že stárneme normálně, a jak stárnout úspěšně** – doc. MUDr. Martin Vyhňálek, Ph.D.
- **Závratě a posturální instabilita ve stáří** – MUDr. Jiří Polívka, CSc., MUDr. Pavel Potužník, Ph.D., Ing. Jiří Polívka, Ph.D.

ODBORNÝ GARANT:

prof. MUDr. Jan Mareš, Ph.D.
Neurologická klinika, FN Olomouc

POŘADATEL: SOLEN, s. r. o.

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN

červen 2023
až květen 2024
dostupný na
online.solen.cz

ZLATÝ
PARTNER

MERCK

